Literature DB >> 4626847

Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.

B Bennett, O D Ratnoff.   

Abstract

Antihemophilic factor (AHF, factor VIII) levels were measured by a standard coagulation method and by an immunologic technique before and after infusion of AHF concentrates into patients with classic hemophilia. After infusion of AHF concentrates, the half-life of the AHF procoagulant (i.e., clot-promoting) activity varied from 12 to 14 hr, whereas that of the antigen ranged from 24 to 40 hr. The half-life of the antigen was similar in patients with and without circulating anticoagulants to AHF. The data are compatible with the suggestion that the antigen may be carried on a precursor molecule which the patient with hemophilia produces but cannot convert to the functional clot-promoting agent. Other explanations of the observations are, however, recognized.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4626847      PMCID: PMC332957          DOI: 10.1172/JCI107076

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  5 in total

1.  The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans.

Authors:  E ADELSON; J J RHEINGOLD; O PARKER; M STEINER; J C KIRBY
Journal:  J Clin Invest       Date:  1963-07       Impact factor: 14.808

2.  THE FATE OF PROTHROMBIN AND FACTORS VIII, IX AND X TRANSFUSED TO PATIENTS DEFICIENT IN THESE FACTORS.

Authors:  R BIGGS; K W DENSON
Journal:  Br J Haematol       Date:  1963-10       Impact factor: 6.998

3.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

4.  Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease.

Authors:  D P Stites; E J Hershgold; J D Perlman; H H Fudenberg
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

5.  Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia.

Authors:  B Bennett; O D Ratnoff; J Levin
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

  5 in total
  5 in total

1.  Factor VIII-related antigen in tissues detected by the indirect immunofluorescence technique.

Authors:  R Gruson; C R Rizza
Journal:  Blut       Date:  1974-10

2.  Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia.

Authors:  B Bennett; O D Ratnoff; J Levin
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

3.  Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

Authors:  J Over; J J Sixma; M H Bruïne; M C Trieschnigg; R A Vlooswijk; N H Beeser-Visser; B N Bouma
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

4.  Haemostatic changes in diabetic coma.

Authors:  R C Paton
Journal:  Diabetologia       Date:  1981-09       Impact factor: 10.122

5.  Interaction of factor VIII antigen in hemophilic plasmas with human antibodies to factor VIII.

Authors:  T S Zimmerman; L de la Pointe; T S Edgington
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.